Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Study of CNTX-6016 in Healthy Subjects for Pain
NCT04154501Phase 1Completed
- Sponsor
- Centrexion Therapeutics
- Start
- Dec 2018
- Primary completion
- Aug 2019
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CNTX-6016 in chronic pain, nociceptive pain and pain (18 cohorts), sponsored by Centrexion Therapeutics. Primary endpoint: Safety of single doses of CNTX-6016 - Treatment-Emergent Adverse Events. Started Dec 2018; status: completed.
02
Drugs
CNTX-6016
03
Conditions
chronic painnociceptive painpain
Beyond the preview
Go deeper on NCT04154501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04154501.